One of the main roles of Public Health England's (PHE) screening quality assurance service (SQAS) is to carry out formal visits to antenatal and newborn screening services. SQAS works with professional and clinical advisors when visiting laboratories providing screening tests for: …
The annual newborn blood spot screening data collection and performance analysis report for the year 1 April 2016 to 31 March 2017.
Ruth Stubbs, PHE's Cervical Screening Programme Manager, shares how the plans for introducing HPV primary screening are coming along.
The NHS Sickle Cell and Thalassaemia Screening Programme has organised 2 laboratory update days in April.
Shared learning in this blog post is specifically aimed at laboratories that provide Down’s, Edwards’ and Patau’s screening.
PHE Screening has published guidance for laboratories and local cervical screening providers to support the option of mitigating against the risk of longer cytology backlogs by using primary HPV screening pilot sites.
NHS England has published a statement regarding commissioning decisions for HPV primary screening in the cervical screening programme.
We’re pleased to announce the publication of an updated version of the antenatal laboratory handbook for the NHS Sickle Cell and Thalassaemia (SCT) Screening Programme.
The breast, bowel and cervical screening programmes require consultant pathologists and other specialist laboratory staff to take part in ‘external quality assessment’ or EQA. But what is EQA exactly?
Cervical screening prevents cancer by detecting abnormalities of the cervix and referring women for potential treatment.